Aliases:This biomarker is also known as:
- neutrophil-activating peptide-2,
- leukocyte-derived growth factor,
- low-affinity platelet factor IV,
- thromboglobulin, beta-1,
- small inducible cytokine subfamily B, member 7,
- small inducible cytokine B7,
- thrombocidin 2,
- thrombocidin 1,
- neutrophil-activating peptide 2,
- connective tissue-activating peptide III,
- CXC chemokine ligand 7,
- pro-platelet basic protein,
- platelet basic protein,
- pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
- macrophage-derived growth factor,
CTAP-III (officially named PPBP) is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and sythesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis. In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers (apolipoprotein A1 (APOA1), truncated transthyretin (TTR), transferrin (TF), hepcidin (HAMP), ÃƒÅ½Ã‚Â²-2 microglobulin B2M), connective tissue activating protein III (CTAPIII, a.k.a PPBP) to CA 125 did not improve sensitivity for preclinical diagnosis of ovarian cancer beyond CA 125 alone.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CTAP-III, also known as PPBP, alone was not a strong predictor.
- HGNC entry for PPBP from Genenames
- KEGG entry for PPBP from Genome.jp
- Entrez entry for PPBP all NCBI Databasese
- Human GEO Profiles for PPBP from NCBI GEO Profiles
- Human Geo Datasets containing term PPBP from NCBI GEO Datasets
- GWAS Study Datasets containing gene PPBP from GWAS
- Human Single Nucleotide Polymorphisms info for PPBP
- Human Gene(s) with 'PPBP ' as Gene Name/Alias
- Human Gene RefSeq for PPBP from NCBI
- UniProtKB/Swiss-Prot entry for PPBP from Uniprot
- Human Protein RefSeq for PPBP from NCBI
- FDA web page describing approval of PPBP
No other associated resources found.
|UniProt Accession #:||P02775|
|Mutated Sites Count:||33|
|Associated Pubmed ID Count||10|
|Affected Protein Function Sites Count:||5|